Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  E-cadherin, GRHL3,  PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 22/April/2019, 9.53 pm

Intracardiac injection of Cyclic helix-B peptide (CHBP) attenuates pathogenesis-associated with Myocardial infarction: Cyclic helix-B peptide (CHBP) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 22/April/2019, 12.07 am
April 21, 2019
Ribonucleic acid-based therapy protects against and promotes functional recovery after Myocardial Infarction:  LncRNA Mirt2 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 22/April/2019, 10.10 pm
April 22, 2019
Show all

What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  E-cadherin, GRHL3,  PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene


The Significance of the study to Public health relevance:

First, given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die due to lack of curative treatment available at present; (ii) cancer deaths globally are expected to be doubled by 2030;  and (iii) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to prevent an individual from being susceptible to cancer by strengthening his/her own immune system (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (iii) a side-effect-free natural product-based anticancer drugs that target cancer stem cells; and (iv) a way to effectively treat and prevent metastatic progression and relapse of ovarian cancers.

Second, given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From research findings to therapeutic opportunity :

(i) Therapeutic strategy:

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings: This study suggests, for the first time, that a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND), by increasing the expression of its target genes, it may: (i) decrease the expression of a number of oncogenes and DNA repair proteins; (ii) increase the expression of tumor/metastasis suppressor genes, such as E-cadherin, GRHL3,  PTPN14; (iii) increase the expression of a number of other tumor suppressor genes, including p53/TA-p73/p63, and their target genes, INKa/p19ARF and others (Figure 1);(iv) activate tumor/metastasis suppressor network; (v) inhibit immunosuppressive/immune-inhibitory receptors/ molecules; (vi) inhibit the activity and proliferation of cancer stem cells; (vii) inhibit tumor growth; and (viii) promote survival (Figures 1-2). Further, the efficacy of Olaparib can be increased by treating cancer patients with a pharmaceutical mixture encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus  (1.0×103 CFU/ml). Thus, a pharmacological formulation encompassingMetformin, Navitoclax/ABT-263, & Dasatinib (MND) or their analogs, either alone or in combination with other known anticancer drugs, or probiotics enriched with anti-cancer activity, such as  Lactobacillus rhamnosus,” may be used to inhibit the progression of advanced  cancers and promote disease-free survival (Figure 3)

Figure 1. Mechanistic insights into how a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) increases the expression of tumor/metastatic suppressors, such as E-cadherin, GRHL3,  PTPN14, p53, TAp73/p63, INK4a, p19ARF and others.

Figure 2.MND functions as a tumor/metastatic suppressors agent not only in advanced cancers but also in mutant-p53 expressing human tumors

Figure 3. A pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, Dasatinib (MND) and probiotic Lactobacillus rhamnosus” may attenuate the progression of advanced  cancers through induction of tumor/metastatic suppressors, such as E-cadherin, GRHL3,  PTPN14, TAp73/p63, INK4a, p19ARF and others

[/caption]  id=”attachment_66254″ align=”alignnone” width=”300″] width=”300″]

Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Amount: $1, 500#

Undisclosed mechanistic information: How does a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) increase the expression of tumor/metastatic suppressors E-cadherin, GRHL3,  & PTPN14?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  E-cadherin, GRHL3,  PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 22/April/2019, 9.53 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, Kindly drop us a line at admin@genomediscovery.org

Comments are closed.